Our studies challenge the conventional understanding of oxygen wastage in inotropy, especially with beta-adrenergic stimuli. The use of a β3 adrenergic receptor antagonist attenuates dobutamine-induced cardiac inefficiency while preserving inotropy, suggesting a complex relationship. Adrenomedullin-epinephrine cotreatment enhances cardiac function through energetically neutral mechanisms, hinting at the possibility of improving performance without increasing oxygen consumption. Another study questions the oxygen-wasting effect of inotropy, emphasizing the need for a reevaluation and suggesting a more nuanced understanding. Together, these findings underscore the controversy around inotropy and oxygen consumption, urging a reconsideration of established notions in cardiac function.
The β3 Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs.
Rødland L, Rønning L, Kildal AB, How OJ.
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):714-723. doi: 10.1177/10742484211048762. Epub 2021 Sep 23.
PMID: 34551626 Free PMC article.
Adrenomedullin-epinephrine cotreatment enhances cardiac output and left ventricular function by energetically neutral mechanisms.
Stenberg TA, Kildal AB, How OJ, Myrmel T.
Am J Physiol Heart Circ Physiol. 2012 Apr 15;302(8):H1584-90. doi: 10.1152/ajpheart.00887.2011. Epub 2012 Feb 3.
PMID: 22307666
Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan.
Müller S, How OJ, Jakobsen Ø, Hermansen SE, Røsner A, Stenberg TA, Myrmel T.
Circ Heart Fail. 2010 Mar;3(2):277-85. doi: 10.1161/CIRCHEARTFAILURE.109.865519. Epub 2009 Dec 16.
PMID: 20018954